GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress on Obesity comparing new-generation weight-loss drugs

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference. And one clearly comes out on top.

Orlistat (sold as Alli) is one effective over-the-counter weight loss aid that is also FDA-approved.

President Trump announced an executive order to significantly reduce U.S. drug prices, aiming to align with costs in other nations. Eli Lilly's Zepbound drug outperforms Wegovy in a weight-loss trial.